The price of the stock the last time has raised by 106.19% from its 52-Week high price while it is -88.91% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 62.59.
The shares of the company added by 8.88% during the trading session on Wednesday, reaching a low of $0.46 while ending the day at $0.52. During the trading session, a total of 3.26 million shares were traded which represents a -62.97% decline from the average session volume which is 2.0 million shares. TRPX had ended its last session trading at $0.48. TRPX 52-week low price stands at $0.25 while its 52-week high price is $4.69.
The Therapix Biosciences Ltd. generated 1.6 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.59 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 14.29%.
Investment analysts at Oppenheimer published a research note on February 28, 2020 where it informed investors and clients that Intellia Therapeutics Inc. (NASDAQ:NTLA) is now rated as Outperform. Wedbush also rated NTLA as Downgrade on February 14, 2020, with its price target of $16 suggesting that NTLA could surge by 14.67% from its current share price. Even though the stock has been trading at $20.26/share, analysts expect it to surge by 10.22% to reach $26.17/share. It started the day trading at $22.96 and traded between $20.50 and $22.33 throughout the trading session.
A look at its technical shows that NTLA’s 50-day SMA is 15.02 while its 200-day SMA stands at 14.19. The stock has a high of $21.63 for the year while the low is $9.18. The stock, however, witnessed a rise in its short on 05/15/20. Compared to previous close which recorded 10.36 M shorted shares, the short percentage went higher by 2.29%, as 10.60M TRPX shares were shorted. At the moment, only 25.48% of Intellia Therapeutics Inc. shares were sold short. The company’s average trading volume currently stands at 883.68K shares, which means that the short-interest ratio is just 12.00 days. Over the past seven days, the company moved, with its shift of 25.10%. Looking further, the stock has raised 50.47% over the past 90 days while it gained 30.74% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The ARK Investment Management LLC bought more NTLA shares, increasing its portfolio by 17.14% during the last quarter. This move now sees The ARK Investment Management LLC purchasing 1,497,854 shares in the last quarter, thus it now holds 10,239,286 shares of NTLA, with a total valuation of $137,923,182. Nikko Asset Management Americas, … meanwhile sold more NTLA shares in the recently filed quarter, changing its stake to $95,519,313 worth of shares.
Similarly, The Vanguard Group, Inc. decreased its Intellia Therapeutics Inc. shares by 1.77% during the recently filed quarter. After selling 3,395,221 shares in the last quarter, the firm now controls -61,262 shares of Intellia Therapeutics Inc. which are valued at $45,733,627. In the same vein, BlackRock Fund Advisors decreased its Intellia Therapeutics Inc. shares by during the most recent reported quarter. The firm bought 20,827 shares during the quarter which decreased its stakes to 3,178,957 shares and is now valued at $42,820,551. Following these latest developments, around 0.10% of Intellia Therapeutics Inc. stocks are owned by institutional investors and hedge funds.